infectious disease when a population is exposed to the parasite. 4 Haldane was the first to suggest that thalassemia heterozygotes are likely to be more resistant to malaria. with high risk of severe malaria infection (e.g cerebral malaria), which confers a high mortality risk. 6 
| PATHOPHYS I OLOGY OF THE S ICKLING MECHANIS M

| Physics and chemistry
The sickling process within red cells occurs as direct consequence of the substitution of a single nucleotide (A to T) in the codon for amino acid 6. The change converts a glutamic acid codon (GAG) to a valine codon (GTG). However, valine is a hydrophobic amino acid. 8 During deoxygenation, valine hydrophobicity attracts hydrophobic regions of adjacent β-chains facilitating the polymerisation of haemoglobin molecules. 9 Formation of Hb aggregates is a thermodynamically unstable event, 10 and under particular conditions, the number of molecules aggregating significantly increases and reaches a critical mass, known as the critical nucleus, after which point addition of further molecules to this compound generates a stable complex.
As this progresses, the reaction becomes autocatalytic and heterogeneous nucleation occurs on the surface of pre-existing polymers, F I G U R E 1 Shown the so-called balanced polymorphism, where the disadvantage of SS homozygotes is balanced by the advantage of AS heterozygotes. Homozygous SCA patients are more likely to die of vaso-occlusive events or to have a short life expectancy because of ongoing vascular occlusion and associated organ damage. Conversely, healthy subjects with normal haemoglobin pattern (HbAA) are more susceptible to malaria infections, particularly during early childhood with high risk of severe malaria infection (e.g cerebral malaria), which carries severe mortality risk. HbS hinders malarial parasites multiplication, and therefore, heterozygotes (HbAS) have an advantage against this disease. The level of HbS in heterozygotes is generally too low to promote severe vaso-occlusive events. These individuals are both protected against malaria and SCA and survive up to the age of reproduction. This creates an evolutionary advantage for this allele, accounting for the high penetrance of the mutation in malarial areas [Colour figure can be viewed at wileyonlinelibrary.com] leading to robust polymer generation, causing erythrocytes sickling. 11 Polymerisation progression is affected by oxygenation, 12, 13 
| The role of KCl channel
The sickling process per se further enhances the activation of the ). 25, 26 Similarly, the release into the circulation of arginase from disrupted red cells reduces plasma arginine levels (the latter being an important NO precursor) further reducing NO level and further damaging the NO-sustained mechanisms of vasodilation.
| Haemolysis and nitric oxide
Furthermore, NO depletion facilitates platelet aggregation and vasoconstriction. Ferric haem enhances endothelial dysfunction through pro-inflammatory damage, favouring vaso-occlusion.
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Taken together, these events, triggered by haemolysis, in part account for vaso-occlusion. The notion that free-Hb scavenges NO is currently believed to be the primum movens in the pathophysiology of SCA vaso-occlusion. It is intriguing to note that recent studies have suggested that red cell transfusion may reduce NO bioavailability by similar mechanisms and increase mortality in patients with coronary artery disease (CAD).
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| Red cell membrane alterations
In SCA, abnormal globin chains cluster along the cell membrane and alter cytoskeletal proteins such as band-3, ankyrin and spectrin. Band-3 is a major integral membrane protein of erythrocytes.
Band-3 is essential for ensuring structural cytoskeletal organisation, the trans-membrane anion transport, the red cell volume regulation and CO 2 removal. Damage of band-3 contributes to sickling processes. The deposition of clusters of globin chains along the cytoskeletal membrane promotes IgG deposition and triggers monocyte chemotaxis leading to removal from circulation of aged red cells. 30, 31 Together with the concomitant changes in structure and function of band-3, these data suggest that sickle RBCs undergo a process of early senescence. Preliminary results show that this process is reversed upon vitamin E supplementation.
Hierso et al 32 showed a reduction of naturally occurring antiband 3 autoantibodies during crises. Furthemore, the diminished antiband 3 antibodies correlated negatively with the rise in plasma advanced oxidation protein products and RBC caspase-3 activity. This clearly suggests a key role for band 3 in sickling crises.
The mechanisms underlying erythrocytes ageing could represent a target, either for a better understanding of sickle cell pathophysiology, but also for possible future therapeutic intervention in sickle cell disease.
An immunological model, known as "the danger model," suggests that immune response is strongly modulated by hydrophobic molecules. 33 In SCA, erythrocyte membrane changes occur leading to exposure of hydrophobic molecules. Moreover, in SCA, microparticle (MP) formation occurs and this phenomenon also participate to vaso-occlusive crisis. 32, [34] [35] [36] Microparticles are rich in hydrophobic molecules such as phosphatidylserine (PS). The exposure of all of these molecules on the surface of red cells will trigger monocyte chemotaxis in an attempt to remove these abnormal cells. Monocytes are increased in numbers and activated during sickle cell crises and trigger sterile inflammation potentially also impacting endothelial cell biology. In addition, monocytes and the red cell fragments will be deposited in the spleen. This process over time will favour the formation of crystalloid inclusions called Gamna-Gandy bodies (GGB). 21 The presence of GGB may also have a link with the development of pulmonary hypertension.
| Adhesion molecules and vaso-occlusion
The vaso-occlusion occurring in sickle cell crises is sustained by several events. One of the key events is the expression on cell sur- the latter also induces tissue factor (TF) expression. 47 P-selectin and E-selectin favour leucocyte rolling and leucocyte-endothelium adhesion. 48 Platelet activation also releases platelet microparticles (PMPs) which also potentiate adhesion and vaso-occlusion process 1. Plasma-free vWF binds subendothelial collagen.
2.
Platelet vWF binds to subendothelial collagen.
Subendothelial collagen binds platelets.
A summary of the key adhesion molecules involved in SCA vasoocclusion is shown in Figure 2 . NO appears to interfere with several of these adhesive pathological processes.
| The role of microparticles
Microparticles (MPs) are intact vesicles derived from cell membrane, whose size varies from 0.2 up to 2.0 μm. They are generated following cell membrane activation. This process has been associated with deregulation of important transmembrane proteins that ensure cell membrane phospholipid asymmetry. The lack of phospholipids asymmetry, with phosphatidylserine exposed on the external lipid layer, has been suggested to increase coagulation in particular thrombin generation. 35 In this context, platelet-derived microparti- 
| Natural anticoagulants and SCA
Protein C (PC) and protein S (PS) levels in adults with SCA are significantly reduced, with the biggest drop occurring during crisis.
Patients on therapy (transfusion programme or hydroxyurea) have similar PC and PS levels to those found in patients in steady state. 61 Similar finding have been reported in children. 34 suggests the presence of a consumptive process contributing to the low levels of PC. 34, 62 Reduced levels of PC and PS seen in SCA are not as dramatic as those seen in sepsis. 64 However, this finding suggests a possible role for anticoagulant therapies for SCA. 65 This is further supported by the results of a randomised doubleblind clinical trial to test the efficacy of a low-molecular-weight heparin in the management of acute painful vaso-occlusive crisis in SCA. This study showed a statistically significant reduction in number of days duration of painful crisis and duration of hospitalisation when tinzaparin was used. 66 In a recent study, 
| Nitric oxide and endothelin-1 in SCA
Aslan et al 67 ).
Ferryl-Hb (Fe
4+
) has an angiotensin-converting enzyme (ACE) inhibitor action and transforms angiotensinogen to angiotensin II, 75 further enhancing vasoconstriction and vaso-occlusion.
| SCA and animal models
Several murine models have been developed to mimic human sickle cell (SS) disease. One of these models, the Berkeley sickle mouse exclusively expresses human sickle hemoglobin and has phenotypic features similar to human sickle cell disease (SCD). 
| Gardos channel inhibitor
| Nitric oxide as a treatment
Aguiar et al 81 suggested that NO and NO precursors should be considered as a possible valid therapy for SCA.
Unfortunately, a double-blind, randomised, placebo-controlled clinical trial comparing inhaled NO versus inhaled nitrogen placebo in patients with sickle cell crises failed to show any benefit in the treatment group. 82 Nevertheless, several authors have recently proven that NO levels are reduced during sickle cell crises and that therapeutical intervention with hydroxyurea re-establishes those levels. 34 Minniti et al 83 also demonstrated that topical sodium nitrite could be useful for leg ulcers. NO-derived drugs could therefore be more useful in complications where haemolytic rate is high (leg ulcers and others) in comparison with vaso-occlusive-like events where the haemolytic rate is lower and NO bioavailability probably less reduced.
Further studies are therefore required to clarify the true role of NO in SCA.
| Mechanism of action of hydroxyurea (HU)
In SCA, HU increases the synthesis of foetal haemoglobin (HbF), reducing HbS production. Recent research studies have also proven that for high-risk children with sickle cell anaemia and abnormal trans cranial Doppler velocities (TCD) who have received at least 1 year of transfusions and have no MRA-defined severe vasculopathy, HU treatment can substitute for chronic transfusions to maintain TCD velocities and help to prevent primary stroke. 84 HU can also work as a nitric oxide (NO) donor. 73 The mechanism of action of HU is several. We here summarise the most relevant modes of action: 
HU increases the release of endothelial NO (Nitric Oxide
| ω-3 treatment
In a recent important study, Wandersee et al 93 blood cell adhesion in patients with SCD. 94 These findings need to be verified in a large multicenter study; however, they suggest that ω-3 fatty acids may be an effective, safe and affordable therapy for sickle cell anaemia.
| Monoclonal antibodies
Interestingly, recent studies by Ataga et al 95 have shown that a newly developed monoclonal antibody against the adhesion molecule Pselectin (Crizanlizumab ® ), significantly reduces the rate of sickle cell pain crises and is associated with a low incidence of adverse events.
| l-Glutamine
Glutamine is a key amino acid involved in the synthesis and production of arginine, nicotinamide (NAD) and glutathione (GSH in SCA has failed to show any benefit in a prospective randomised trial. 108 This supports the view that vaso-occlusion is a heterogeneous and highly complex event in which platelet activation is only one of many pathophysiological mechanisms. 
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